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Human arterial hypertension revisited:
How to leap from animal models to individually
tailored therapy?
It all started many decades ago when first data linked arterial hy-
pertension with sudden deaths. The rest is a long history of research
and achievements that made us believe in different culprits for this
plague of modern man. In fact, this story could have been a fairy tale
beginning:
Once upon a time, in the Land of Human Suffering, just beyond the
Solid Tumor Swamps lay the waste Land of Arterial Hypertension. In the
middle of it is the foggy Hypertension Forest, surrounded by several villages
inhabited by scientists of various kinds. The two biggest are held by Nephro-
logists and by Cardiologists, in the third dwell together many Physiologists
and Pathophysiologists.
All these people are hunters, trying to find the magic tree of human hy-
pertension among many trees in the forest. The legend says that if the tree is
found and cut down, the whole waste land would disappear, thus ending
human suffering from arterial hypertension. The problem is that, due to
fog, seeing which tree might be the right one is hard.
These hunters are helped by their pets in this quest. Most of them prefer
rats. It is interesting that instead of taking the pets to the wood, they use rats
for all kind of tests. Later, hunters use the acquired knowledge to find the
path through the wood. There was a rumor that many years ago the
Nephrologists used dogs and found an important tree, the legendary Reno-
vascular Hypertension Tree that no longer exists, but this is just a legend,
and the Nephrologists are also using rats these days. For instance, few de-
cades ago, rats helped them to find few Natriuretic trees that turned out to
be much less important than expected. It was a huge disappointment.
All villagers are supported by traveling magicians called Pharmaceuti-
cals that bring them various magic lotion and other stuff that might help
them find and cut down the tree.
The hunters from all villages occasionally meet on rare festive days, usu-
ally far away from the wood, somewhere on the seaside, free of fog and dark
forests. There they talk mostly about their pets and about the wood. Some
says that all trees in the wood are pines, the other has seen only shrubbery,
while the third is talking about mighty oaks. It often ends in a quarrel, but,
occasionally they realize that all their differences come from the fog and
their separate paths through the forest.
Far away, in their high tower, a small bunch of Epidemiologists watch
over the Land of Human Suffering using sharp binoculars. On rare sunny
days, they can clearly see the Forest of Human Hypertension in the distance,
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Essays
almost without any fog. Then, it seems to them that the for-
est has just few huge trees and lots of small ones that look
almost like the rat trees. Nevertheless, who will know for
shure from that distance, and the quest continues in the
deep forest...
During several decades research on arterial hyperten-sion focused on several issues: kidney perfusion in
Goldblat's hypertension, dietary salt intake and renal ex-
cretion, roles of atrial and other natriuretic factors, in-
creased exposure to vasoconstrictors (norepinephrine, epi-
nephrine, vasopressin, angiotensin II, endothelin-I), re-
duced local vasodilatatory actions (nitric oxide, adeno-
sine etc.). Recent advancement of molecular biology turned
our attention to intracellular mechanisms and gene ex-
pression. Less popular but still active field is the link of
ageing and suboptimal reparatory angiogenesis that leads
to slow increases in peripheral vascular resistance, caus-
ing compensatory hypertension in individuals with nor-
mal, or hypertrophied heart muscle. It seems reasonably
to expect that the less understood areas in human hyper-
tension can be related to epigenetic changes. If these
changes accumulate in young individuals, they can alter
the hypertension risk in their offspring (1).
The potential problem is that most of our knowledge
about arterial hypertension comes from several animal
model, usually on rats. After several years of animal test-
ing new drugs are tested on patients in well organized
trials and finally compared with standard treatments in
large phase III trials that take several hundreds or even
thousands of patients.
An example that important data can be lost along the
described path is recently recognized fact that ingestion
of fructose rich soft drinks can lead to hypertension in
human (2). It was only recently found in an epidemio-
logical study, since animal data on this topic from 1987
(3) and 1994 (4) were not recognized as relevant, de-
spite their publication in a leading journal. So we had to
wait two decades for the epidemiology data to correct
our dietary salt-centered interpretation of arterial hy-
pertension.
As an illustration, two important topics in human ar-
terial hypertension that seem hardly testable in animal
models are listed:
– hypertension due to aging that leads to suboptimal
reparatory angiogenesis and vascular damage en-
hanced by accumulated oxidative stress.
the role of human cognition and stored memories
in hypertension. Large clinical studies report that
patients with Alzheimer’s disease normalize previ-
ously elevated blood pressure. Among previously
hypertensive, elderly persons, an unexpected mi-
nority of hypotensive elderly patients with cogni-
tive decline has been found (5, 6).
When considering size of current clinical trials of
antihypertensive drugs, it seems that bitter remarks of
D.F. Horrobin (7) on oncological trials hold true also
here. He said: »... Many drugs show statistically significant
benefits with trial sizes of 20 or 30 patients. With such drugs
the prescribing physicians can know that most treated pa-
tients will show a response that can be reasonably attributed
to the drug by both patient and doctor. But as effect sizes be-
come smaller and trial sizes climb over a hundred, it be-
comes more and more difficult for anyone to know whether
what happens to the individual was caused by the drug.«
The need for a faster pipeline and smaller, less expen-
sive trials is obvious. Optimal trial size would be the one
that can discard any potential drugs unless it is more
than just marginally beneficial. This would force phar-
maceutical companies to pursue several goals simulta-
neously instead of their current practice to place all bets
on one or few horses.
Since decades of almost a uniform approach to the
treatment of hypertensive patients, based on large clini-
cal trials, have already reached their »glass ceiling« of
clinical efficacy, any substantial improvement can come
from the individually tailored therapy. To achieve that,
we need to dissolve the entity of arterial hypertension in
several closely related diseases that require different ther-
apeutic approaches. The goal would be to divide patients
based on their specific features and then apply optimal,
individually tailored, holistic therapy that would address
the causative mechanism in that individual. The holistic
treatment would need to include preventive measure and
lifestyle changes before chronic medication, something
completely different from the contemporary practice.
If we try to look in the future of arterial hypertension
treatment, a potential path is to put more effort on:
– hereditary traits in relatives with and without hy-
pertension despite different lifestyle habits and ex-
posures to known prohypertensive factors
– exposure risk in unrelated individuals with and
without hypertension despite a similar lifestyle and
exposures to known prohypertensive factors.
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